You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
通化東寶(600867.SH):預混型門冬胰島素注射液獲得報產受理通知
格隆匯 07-14 15:40

格隆匯7月14日丨通化東寶(600867.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的關於門冬胰島素50注射液和門冬胰島素30注射液申報生產的受理通知書,受理號為CXSS2101010國、CXSS2101012國。

門冬胰島素是一種速效的胰島素類似物,其降血糖作用是通過與肌肉和脂肪細胞上的胰島素受體結合後,促進細胞對葡萄糖吸收利用,同時抑制肝臟葡萄糖的輸出來實現的。門冬胰島素活性成份根據生產工藝不同,可分別製成注射液和預混型注射液。此次公司所申報受理的預混型門冬胰島素注射液為2個品種,分別為門冬胰島素50注射液和門冬胰島素30注射液。

諾和諾德在2020年財報中公佈了其門冬胰島素注射液和預混型門冬胰島素注射在全球的銷售額約為365.62億丹麥克朗(摺合人民幣約為394.37億元);在大中華區,包括中國大陸、香港和台灣的銷售額約為68.88億丹麥克朗(摺合人民幣約為74.30億元)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account